Clinical trials: Heart Failure With Reduced Ejection Fraction, active
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure With Reduced Ejection Fraction
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.
- Trial name
- RECOVER-HF (NCT06552637)
- Testing
- Synchronized Diaphragmatic Stimulation
- Where
- 5 sites in United States, Georgia
- Volunteers
- 270 people
- Sponsor
- VisCardia Inc.
Heart Failure With Reduced Ejection Fraction
HFrEF Polypill in Sri Lanka RCT
The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure…
- Trial name
- NCT07569640
- Testing
- Usual Care, HFrEF Polypill
- Where
- 12 sites in Sri Lanka
- Volunteers
- 1,672 people
- Sponsor
- Washington University School of Medicine
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function.
- Conditions
- Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF), Rate Control
- Trial name
- NCT07272902
- Testing
- Catheter Ablation for Atrial Fibrillation, Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)
- Where
- 4 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Nova Scotia Health Authority
Heart Failure, Acute Heart Failure
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure.
- Conditions
- Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PopS-HF (NCT07295522)
- Testing
- Guideline-Directed Medical Therapy (GDMT)
- Where
- 12 sites in Italy
- Volunteers
- 368 people
- Sponsor
- IRCCS Policlinico S. Donato
Heart Failure With Reduced Ejection Fraction (HFrEF)
Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction
The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure…
- Trial name
- OLEA-HF (NCT07644806)
- Testing
- Extra-virgin olive oil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Old Dominion University
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF)
Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
Atrial Fibrillation (AF) and Heart Failure (HF) are colliding global cardiovascular epidemics, individually impairing quality of life and cardiac performance, as well as increasing the risk of hospitalisation and mortality.
- Trial name
- OPTIMal AF-HF (NCT07238452)
- Testing
- Pulmonary Vein Isolation, Pharmacological Rate Control
- Volunteers
- 1,050 people
- Sponsor
- University of British Columbia
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 209 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.
HFrEF - Heart Failure With Reduced Ejection Fraction, Guideline Adherence
Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)
The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4…
- Trial name
- IMPLEMENT HF (NCT07702760)
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Jasper Brugts MD PhD
Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis)
Prospective Evaluation of AI-ECG for SHD Detection
AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart disease in adults undergoing…
- Conditions
- Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis), Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis), Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
- Trial name
- AI-ECG-SHD (NCT07057466)
- Testing
- Traditional 12-lead Electrocardiogram, Apple Watch Series 4 Single-lead Electrocardiogram, Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram
- Where
- 6 sites in United Kingdom
- Volunteers
- 590 people
- Sponsor
- Imperial College London
Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Home-Based Cardiac Rehabilitation for Patients With Heart Failure
The vast majority of individuals with heart failure do not participate in center based cardiac rehabilitation (CBCR). While steps to increase utilization of CBCR are important, many individuals will still not participate for a…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases
- Trial name
- MOBILE HEART (NCT06479876)
- Testing
- HBCR
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild
[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction
Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Trial name
- NEURO-HF (NCT07856043)
- Testing
- [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stony Brook University
Heart Failure With Reduced Ejection Fraction
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction…
- Trial name
- NCT07465653
- Testing
- HJB647 low dose, HJB647 high dose
- Where
- 6 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency (ID), Heart Failure
Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure
The INITIATE-HF study is a cluster randomized controlled trial that aims to find out if reminding doctors about treatment guidelines for iron deficiency in adults with heart failure who are hospitalized and have evidence of iron…
- Conditions
- Iron Deficiency (ID), Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- INITIATE-HF (NCT07467668)
- Testing
- Notification Group, No Notification Group
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Kaiser Permanente
Heart Failure With Reduced Ejection Fraction, HFrEF - Heart Failure With Reduced Ejection Fraction
Intermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy
This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical…
- Trial name
- NCT07845201
- Volunteers
- 250 people
- Sponsor
- Assiut University
Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure
Vericiguat and Reverse Remodeling Indices in Heart Failure
The goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy.
- Trial name
- VERI-PATH (NCT07405944)
- Testing
- Vericiguat, Guideline Directed Medical Therapy for Heart Failure (GDMT)
- Where
- 4 sites in Slovenia
- Volunteers
- 70 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection…
- Trial name
- Elevate-HF (NCT07761117)
- Testing
- Elecoglipron
- Where
- 679 sites in United States, Argentina and 30 more
- Volunteers
- 6,950 people
- Sponsor
- AstraZeneca